This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.
The lawsuit argued that Gilead subsidiary Kite Therapeutics infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and Memorial Sloan Kettering Cancer Centre for exclusive rights to its ... BMS alleged that Kite scientists copied
EQRx is co-founded by Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center whose academic interests focus on pricing as well as
Memorial Sloan Kettering Cancer Center for the exclusive rights to the technology. ... We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," it said.
Tepotinib also seemed to work in patients with brain metastases who “benefitted equally” from treatment, according to lead investigator Paul Paik of Memorial Sloan Kettering Cancer Centre in the US.
Last week’s business reshuffle also saw Memorial Sloan Kettering Cancer Center physician José Baselga brought in to head the company’s cancer R&D unit – a somewhat controversial choice given
Dr José Baselga. Dr Baselga – formerly chief medical officer at Memorial Sloan Kettering Cancer Centre – becoming head of cancer R&D.
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Strategies for sourcing external innovation include collaborations with universities and leading academic research centers based on their research focus (eg, oncology companies partnering with Memorial Sloan Kettering Cancer Center) and geographic
He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial Sloan Kettering Cancer Center as an example.
No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine
Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and
Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...